The potential role of epigenetic therapy in multiple myeloma

British Journal of Haematology

Volumn 148, Issue 5, 2010, Pages 702-713

  Smith, Emma M ^a   Boyd, Kevin ^a   Davies, Faith E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Clinical trials; Epigenetics; Molecular haematology; Myeloma; Oncology; Therapy

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEHYDRODIDEMNIN B; DEXAMETHASONE; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; KD 5170; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PROTEIN P53; RESVERATROL; ROMIDEPSIN; SRT 501; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CELL CYCLE ARREST; CLINICAL TRIAL; CONSTIPATION; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DIARRHEA; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME ACTIVITY; EPIGENETICS; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; INFECTION; LIVER FUNCTION TEST; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOMA; MYELOMA CELL; MYOPATHY; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MODIFICATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MULTIPLE MYELOMA;

EID: 76449105686     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07976.x     Document Type: Review

References (115)

1. Adler, A.J., Fasman, G.D., Wangh, L.J. Allfrey, V.G. (1974) Altered conformational effects of naturally acetylated histone f2al (IV) in f2al-deoxyribonucleic acid complexes. Circular dichroism studies. The Journal of Biological Chemistry, 249, 2911 2914.
2. Aoyama, T., Okamoto, T., Kohno, Y., Fukiage, K., Otsuka, S., Furu, M., Ito, K., Jin, Y., Nagayama, S., Nakayama, T., Nakamura, T. Toguchida, J. (2008) Cell-specific epigenetic regulation of ChM-I gene expression: crosstalk between DNA methylation and histone acetylation. Biochemical and Biophysical Research Communications, 365, 124 130.
3. Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E. Bhalla, K. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. Journal of Biological Chemistry, 280, 26729 26734.
4. Baylin, S.B. Herman, J.G. (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends in Genetics, 16, 168 174.
5. Benetatos, L., Dasoula, A., Hatzimichael, E., Georgiou, I., Syrrou, M. Bourantas, K. (2008) Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clinical Lymphoma & Myeloma, 8, 171 175.
6. Bhardwaj, A., Sethi, G., Vadhan-Raj, S., Bueso-Ramos, C., Takada, Y., Gaur, U., Nair, A.S., Shishodia, S. Aggarwal, B.B. (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109, 2293 2302.
7. Biel, M., Wascholowski, V. Giannis, A. (2005) Epigenetics - an epicenter of gene regulation: histones and histone-modifying enzymes. Angewandte Chemie International Edition, 44, 3186 3216.
8. Boissy, P., Andersen, T.L., Abdallah, B.M., Kassem, M., Plesner, T. Delaisse, J.M. (2005) Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Research, 65, 9943 9952.
9. Bolden, J.E., Peart, M.J. Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews. Drug Discovery, 5, 769 784.
10. Bollati, V., Fabris, S., Pegoraro, V., Ronchetti, D., Mosca, L., Deliliers, G.L., Motta, V., Bertazzi, P.A., Baccarelli, A. Neri, A. (2009) Differential repetitive DNA methylation in Multiple Myeloma molecular subgroups. Carcinogenesis, 30, 1330 1335.
11. Brito, J.L., Walker, B., Jenner, M., Dickens, N.J., Brown, N.J., Ross, F.M., Avramidou, A., Irving, J.A., Gonzalez, D., Davies, F.E. Morgan, G.J. (2009) MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica, 94, 78 86.
12. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G. Baylin, S.B. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics, 21, 103 107.
13. Carew, J.S., Giles, F.J. Nawrocki, S.T. (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Letters, 269, 7 17.
14. de Carvalho, F., Colleoni, G.W.B., Sampaio Almeida, M.S., Carvalho, A.L. Vettore, A.L. (2009) TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. International Journal of Cancer, 125, 1985 1991.
15. Catley, L., Weisberg, E., Tai, Y.-T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., Shringarpure, R., LeBlanc, R., Chauhan, D., Munshi, N.C., Schlossman, R., Richardson, P., Griffin, J. Anderson, K.C. (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102, 2615 2622.
16. Catley, L., Weisberg, E., Kiziltepe, T., Tai, Y.T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N.C. Anderson, K.C. (2006) Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood, 108, 3441 3449.
17. Chen, G., Wang, Y., Huang, H., Lin, F., Wu, D., Sun, A., Chang, H. Feng, Y. (2009) Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. European Journal of Haematology, 82, 176 183.
18. Cheng, S.H., Ng, M.H.L., Lau, K.M., Liu, H.S.Y., Chan, J.C.W., Hui, A.B.Y., Lo, K.W., Jiang, H., Hou, J., Chu, R.W., Wong, W.S., Chan, N.P.H. Ng, H.K. (2007) 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. Blood, 109, 2089 2099.
19. Choi, J.H., Kwon, H.J., Yoon, B.I., Kim, J.H., Han, S.U., Joo, H.J. Kim, D.Y. (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Japanese Journal of Cancer Research, 92, 1300 1304.
20. Costello, J.F., Fruhwald, M.C., Smiraglia, D.J., Rush, L.J., Robertson, G.P., Gao, X., Wright, F.A., Feramisco, J.D., Peltomaki, P., Lang, J.C., Schuller, D.E., Yu, L., Bloomfield, C.D., Caligiuri, M.A., Yates, A., Nishikawa, R., Su Huang, H.J., Petrelli, N.J., Zhang, X., O'Dorisio, M.S., Held, W.A., Cavenee, W.K. Plass, C. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genetics, 24, 132 138.
21. Davenport, E.L., Moore, H.E., Dunlop, A.S., Sharp, S.Y., Workman, P., Morgan, G.J. Davies, F.E. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood, 110, 2641 2649.
22. Dokmanovic, M., Clarke, C. Marks, P.A. (2007) Histone deacetylase inhibitors: overview and perspectives. Molecular Cancer Research, 5, 981 989. (Pubitemid 350080267)
23. Eden, A., Gaudet, F., Waghmare, A. Jaenisch, R. (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 300, 455.
24. Espada, J., Ballestar, E., Fraga, M.F., Villar-Garea, A., Juarranz, A., Stockert, J.C., Robertson, K.D., Fuks, F. Esteller, M. (2004) Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. Journal of Biological Chemistry, 279, 37175 37184.
25. Fandy, T.E., Shankar, S., Ross, D.D., Sausville, E. Srivastava, R.K. (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7, 646 657.
26. Feinberg, A.P. Tycko, B. (2004) The history of cancer epigenetics. Nature Reviews. Cancer, 4, 143 153.
27. Feng, R., Ma, H., Hassig, C.A., Payne, J.E., Smith, N.D., Mapara, M.Y., Hager, J.H. Lentzsch, S. (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Molecular Cancer Therapeutics, 7, 1494 1505.
28. Fuks, F., Burgers, W.A., Brehm, A., Hughes-Davies, L. Kouzarides, T. (2000) DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nature Genetics, 24, 88 91.
29. Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Bosi, A., Crippa, C., Rossi, G., Pescosta, N., Cortelazzo, S., Sechi, A., Oldoni, T. Rambaldi, A. (2007) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results. Blood (ASH Annual Meeting Abstracts), 110, 1175.
30. Galm, O., Yoshikawa, H., Esteller, M., Osieka, R. Herman, J.G. (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood, 101, 2784 2788.
31. Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., Leonhardt, H. Jaenisch, R. (2003) Induction of tumors in mice by genomic hypomethylation. Science, 300, 489 492.
32. Golay, J., Cuppini, L., Leoni, F., Mico, C., Barbui, V., Domenghini, M., Lombardi, L., Neri, A., Barbui, A.M., Salvi, A., Pozzi, P., Porro, G., Pagani, P., Fossati, G., Mascagni, P., Introna, M. Rambaldi, A. (2007) The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia, 21, 1892 1900.
33. van Haaften, G., Dalgliesh, G.L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., Butler, A., Hinton, J., Latimer, C., Andrews, J., Barthorpe, S., Beare, D., Buck, G., Campbell, P.J., Cole, J., Forbes, S., Jia, M., Jones, D., Kok, C.Y., Leroy, C., Lin, M.-L., McBride, D.J., Maddison, M., Maquire, S., McLay, K., Menzies, A., Mironenko, T., Mulderrig, L., Mudie, L., Pleasance, E., Shepherd, R., Smith, R., Stebbings, L., Stephens, P., Tang, G., Tarpey, P.S., Turner, R., Turrell, K., Varian, J., West, S., Widaa, S., Wray, P., Collins, V.P., Ichimura, K., Law, S., Wong, J., Yuen, S.T., Leung, S.Y., Tonon, G., DePinho, R.A., Tai, Y.-T., Anderson, K.C., Kahnoski, R.J., Massie, A., Khoo, S.K., Teh, B.T., Stratton, M.R. Futreal, P.A. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genetics, 41, 521 523.
34. Halkidou, K., Gaughan, L., Cook, S., Leung, H.Y., Neal, D.E. Robson, C.N. (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. The Prostate, 59, 177 189.
35. Harrison, S.J., Quach, H., Yuen, K., Strayer, A., Copeman, M.C., Peinert, S., Bishton, M., Wolf, M., Januszewicz, H., Kenealy, M.K., Herbert, K., Westerman, D., Carney, D., Seymour, J.F., Johnstone, R.W., Ritchie, D. Prince, M. (2008) High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. Blood (ASH Annual Meeting Abstracts), 112, 3698.
36. Hatzimichael, E., Dranitsaris, G., Dasoula, A., Benetatos, L., Stebbing, J., Crook, T. Bourantas, K. (2009a) von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clinical Lymphoma & Myeloma, 9, 239 242.
37. Hatzimichael, E., Benetatos, L., Dasoula, A., Dranitsaris, G., Tsiara, S., Georgiou, I., Syrrou, M., Stebbing, J., Coley, H.M., Crook, T. Bourantas, K.L. (2009b) Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. Leukemia Research, 33, 1272 1275.
38. Heller, G., Schmidt, W.M., Ziegler, B., Holzer, S., Mullauer, L., Bilban, M., Zielinski, C.C., Drach, J. Zochbauer-Muller, S. (2008) Genome-wide transcriptional response to 5-Aza-2′-Deoxycytidine and trichostatin A in multiple myeloma cells. Cancer Research, 68, 44 54.
39. Heltweg, B., Gatbonton, T., Schuler, A.D., Posakony, J., Li, H., Goehle, S., Kollipara, R., DePinho, R.A., Gu, Y., Simon, J.A. Bedalov, A. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Research, 66, 4368 4377.
40. Hideshima, T., Bradner, J.E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S.L. Anderson, K.C. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 102, 8567 8572.
41. Hodge, D.R., Peng, B., Cherry, J.C., Hurt, E.M., Fox, S.D., Kelley, J.A., Munroe, D.J. Farrar, W.L. (2005) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Research, 65, 4673 4682.
42. Illingworth, R., Kerr, A., DeSousa, D., Jorgensen, H., Ellis, P., Stalker, J., Jackson, D., Clee, C., Plumb, R., Rogers, J., Humphray, S., Cox, T., Langford, C. Bird, A. (2008) A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biology, 6, e22.
43. Jang, K.Y., Hwang, S.H., Kwon, K.S., Kim, K.R., Choi, H.N., Lee, N.R., Kwak, J.Y., Park, B.H., Park, H.S., Chung, M.J., Kang, M.J., Lee, D.G., Kim, H.S., Shim, H. Moon, W.S. (2008) SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. American Journal of Surgical Pathology, 32, 1523 1531.
44. Jost, E., Gezer, D., Wilop, S., Suzuki, H., Herman, J.G., Osieka, R. Galm, O. (2009) Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Cancer Letters, 281, 24 31.
45. Jung-Hynes, B., Nihal, M., Zhong, W. Ahmad, N. (2009) Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?. The Journal of Biological Chemistry, 284, 3823 3832.
46. Kabra, N., Li, Z., Chen, L., Li, B., Zhang, X., Wang, C., Yeatman, T., Coppola, D. Chen, J. (2009) SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. Journal of Biological Chemistry, 284, 18210 18217.
47. Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Kloetzel, P.M., Sezer, O. Heider, U. (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica, 91, 248 251.
48. Kawaguchi, Y., Kovacs, J.J., McLaurin, A., Vance, J.M., Ito, A. Yao, T.-P. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 115, 727 738.
49. Khan, S.B., Maududi, T., Barton, K., Ayers, J. Alkan, S. (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. British Journal of Haematology, 125, 156 161.
50. Khong, T., Sharkey, J. Spencer, A. (2008) The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica, 93, 860 869.
51. Kim, J.Y., Kee, H.J., Choe, N.W., Kim, S.M., Eom, G.H., Baek, H.J., Kook, H., Kook, H. Seo, S.B. (2008) Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Molecular and Cellular Biology, 28, 2023 2034.
52. Kiziltepe, T., Hideshima, T., Catley, L., Raje, N., Yasui, H., Shiraishi, N., Okawa, Y., Ikeda, H., Vallet, S., Pozzi, S., Ishitsuka, K., Ocio, E.M., Chauhan, D. Anderson, K.C. (2007) 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Molecular Cancer Therapeutics, 6, 1718 1727.
53. Kopito, R.R. (2000) Aggresomes, inclusion bodies and protein aggregation. Trends in Cell Biology, 10, 524 530.
54. Krejcí, J., Harnicarová, A., Streitová, D., Hájek, R., Pour, L., Kozubek, S. Bártová, E. (2009) Epigenetics of multiple myeloma after treatment with cytostatics and gamma radiation. Leukemia Research, 33, 1490 1498.
55. Kuehl, W.M. Bergsagel, P.L. (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews. Cancer, 2, 175 187.
56. Langley, E., Pearson, M., Faretta, M., Bauer, U.M., Frye, R.A., Minucci, S., Pelicci, P.G. Kouzarides, T. (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO Journal, 21, 2383 2396.
57. Lavelle, D., Chen, Y.H., Hankewych, M. DeSimone, J. (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. American Journal of Hematology, 68, 170 178.
58. Lin, R.J., Sternsdorf, T., Tini, M. Evans, R.M. (2001) Transcriptional regulation in acute promyelocytic leukemia. Oncogene, 20, 7204 7215.
59. Liu, T., Liu, P.Y. Marshall, G.M. (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Research, 69, 1702 1705.
60. Lu, Q., Lin, X., Feng, J., Zhao, X., Gallagher, R., Lee, M.Y., Chiao, J.W. Liu, D. (2008) Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. Journal of Hematology & Oncology, 1, 6.
61. Lujambio, A., Ropero, S., Ballestar, E., Fraga, M.F., Cerrato, C., Setien, F., Casado, S., Suarez-Gauthier, A., Sanchez-Cespedes, M., Gitt, A., Spiteri, I., Das, P.P., Caldas, C., Miska, E. Esteller, M. (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Research, 67, 1424 1429.
62. Marango, J., Shimoyama, M., Nishio, H., Meyer, J.A., Min, D.J., Sirulnik, A., Martinez-Martinez, Y., Chesi, M., Bergsagel, P.L., Zhou, M.M., Waxman, S., Leibovitch, B.A., Walsh, M.J. Licht, J.D. (2008) The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood, 111, 3145 3154.
63. Mateos, M.V., García-Sanz, R., López-Pérez, R., Moro, M.J., Ocio, E., Hernández, J., Megido, M., Caballero, M.D., Fernández-Calvo, J., Bárez, A., Almeida, J., Orfão, A., González, M. Miguel, J.F.S. (2002) Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. British Journal of Haematology, 118, 1034 1040.
64. Mateos, M.-V., Cibeira, M.T., Richardson, P., Blade, J., Prosper, F., Oriol, A., de la Rubia, J., Alegre, A., Lahuerta, J.J., Garcia-Sanz, R., Mitsiades, C.S., Espinoza, J., Anderson, K.C. Miguel, J.F.S. (2008) Final results of a phase II trial with plitidepsin (aplidin) alone and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, 3700.
65. Mazumder, A., Vesole, D.H. Jagannath, S. (2008) Treatment of multiple myeloma with vorinostat in combination with bortezomib: a case series. Blood (ASH Annual Meeting Abstracts), 112, 5213.
66. Milutinovic, S., D'Alessio, A.C., Detich, N. Szyf, M. (2007) Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis, 28, 560 571.
67. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., McMullan, C., Poulaki, V., Fanourakis, G., Schlossman, R., Chauhan, D., Munshi, N.C., Hideshima, T., Richon, V.M., Marks, P.A. Anderson, K.C. (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 101, 4055 4062.
68. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. Anderson, K.C. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 101, 540 545.
69. Mitsiades, C.S., McMillin, D.W., Klippel, S., Hideshima, T., Chauhan, D., Richardson, P.G., Munshi, N.C. Anderson, K.C. (2007) The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematology/Oncology Clinics of North America, 21, 1007 1034.
70. Ng, M.H.L., Chung, Y.F., Lo, K.W., Wickham, N.W.R., Lee, J.C.K. Huang, D.P. (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood, 89, 2500 2506.
71. Ng, M.H.L., To, K.W., Lo, K.W., Chan, S., Tsang, K.S., Cheng, S.H. Ng, H.K. (2001) Frequent Death-associated Protein Kinase Promoter Hypermethylation in Multiple Myeloma. Clinical Cancer Research, 7, 1724 1729.
72. Nojima, M., Maruyama, R., Yasui, H., Suzuki, H., Maruyama, Y., Tarasawa, I., Sasaki, Y., Asaoku, H., Sakai, H., Hayashi, T., Mori, M., Imai, K., Tokino, T., Ishida, T., Toyota, M. Shinomura, Y. (2009) Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clinical Cancer Research, 15, 4356 4364.
73. Okano, M., Bell, D.W., Haber, D.A. Li, E. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 99, 247 257.
74. Ou, J.-N., Torrisani, J., Unterberger, A., Provençal, N., Shikimi, K., Karimi, M., Ekström, T.J. Szyf, M. (2007) Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochemical Pharmacology, 73, 1297 1307.
75. Peng, B., Hurt, E.M., Hodge, D.R., Thomas, S.B. Farrar, W.L. (2006) DNA hypermethylation and partial gene silencing of human thymine- DNA glycosylase in multiple myeloma cell lines. Epigenetics, 1, 138 145.
76. Primeau, M., Gagnon, J. Momparler, R.L. (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2prime-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. International Journal of Cancer, 103, 177 184.
77. Rahmani, M., Yu, C., Dai, Y., Reese, E., Ahmed, W., Dent, P. Grant, S. (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Research, 63, 8420 8427.
78. Rao, R., Fiskus, W., Yang, Y., Lee, P., Joshi, R., Fernandez, P., Mandawat, A., Atadja, P., Bradner, J.E. Bhalla, K. (2008) HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood, 112, 1886 1893.
79. Rascle, A., Johnston, J.A. Amati, B. (2003) Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Molecular and Cellular Biology, 23, 4162 4173.
80. Recillas-Targa, F. (2002) DNA methylation, chromatin boundaries, and mechanisms of genomic imprinting. Archives of Medical Research, 33, 428 438.
81. Richardson, P.G., Mitsiades, C.S., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J.L., Rizvi, S., Oerth, C., Atkins, B., Fearen, I., Anderson, K.C. Siegel, D.S. (2007) Final results of a phase I trial of oral vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced multiple myeloma. Blood (ASH Annual Meeting Abstracts), 110, 1179.
82. Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., Atkins, B., Fearen, I., Anderson, K. Siegel, D. (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia and Lymphoma, 49, 502 507. (Pubitemid 351298334)
83. Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C., Coetzee, G.A. Jones, P.A. (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 9, 435 443.
84. Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Kiriyama, M., Fukai, I., Yamakawa, Y. Fujii, Y. (2004) Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer, 46, 171 178. (Pubitemid 39330411)
85. Seidl, S., Ackermann, J., Kaufmann, H., Keck, A., Nösslinger, T., Zielinski, C.C., Drach, J. Zöchbauer-Müller, S. (2004) DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer, 100, 2598 2606.
86. Selker, E.U. (1998) Trichostatin A causes selective loss of DNA methylation in Neurospora. Proceedings of the National Academy of Sciences of the United States of America, 95, 9430 9435.
87. Shankar, S. Srivastava, R.K. (2008) Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Advances in Experimental Medicine and Biology, 615, 261 298.
88. Siegel, D., Sezer, O., San Miguel, J.F., Mateos, M.-V., Prosser, I., Cavo, M., Jalaluddin, M., Hazell, K., Bourquelot, P.M. Anderson, K.C. (2008) A Phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, 2781.
89. Siegel, D., Weber, D., Mitsiades, C., Rizvi, S., Howe, J., Reiser, D., Anderson, K. Richardson, P. (2009) Vorinostat/lenalidomide/dexamethasone: a phase I study. Clinical Lymphoma & Myeloma, Abstracts Presented at the 13th Annual International Congress on Hematologic Malignancies, 9, S41.
90. Song, J., Noh, J.H., Lee, J.H., Eun, J.W., Ahn, Y.M., Kim, S.Y., Lee, S.H., Park, W.S., Yoo, N.J., Lee, J.Y. Nam, S.W. (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS, 113, 264 268.
91. Spurling, C.C., Godman, C.A., Noonan, E.J., Rasmussen, T.P., Rosenberg, D.W. Giardina, C. (2008) HDAC3 overexpression and colon cancer cell proliferation and differentiation. Molecular Carcinogenesis, 47, 137 147.
92. Sullivan, D., Singhal, S., Schuster, M., Berenson, J., Gimsing, P., Wisloff, F., Waage, A., Alsina, M., Gerwien, R., Clarke, A., Moller, K. Ooi, C.E. (2006) A phase II study of PXD101 in advanced multiple myeloma. Blood (ASH Annual Meeting Abstracts), 108, 3583.
93. Sun, C., Hu, Y., Liu, X., Wu, T., Wang, Y., He, W. Wei, W. (2006) Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genetics and Cytogenetics, 165, 9 19.
94. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. Gu, W. (2008) Acetylation is indispensable for p53 activation. Cell, 133, 612 626.
95. Toh, Y., Yamamoto, M., Endo, K., Ikeda, Y., Baba, H., Kohnoe, S., Yonemasu, H., Hachitanda, Y., Okamura, T. Sugimachi, K. (2003) Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncology Reports, 10, 333 338.
96. Tshuikina, M., Jernberg-Wiklund, H., Nilsson, K. Oberg, F. (2008) Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. Experimental Hematology, 36, 1673 1681.
97. Ullmannova-Benson, V., Guan, M., Zhou, X., Tripathi, V., Yang, X.Y., Zimonjic, D.B. Popescu, N.C. (2008) DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia, 23, 383 390.
98. Ulrike, H., Ivana von, M., Martin, K., Marleen, R., Jan, S., Susanne, R., Jessica, R., Christian, J., Claudia, F., Ulrike, K., Peter-Michael, K. Orhan, S. (2008) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. European Journal of Haematology, 80, 133 142.
99. Ulrike, H., Jessica, R., Britta, L., Maren, M., Markus, M., Ivana von, M., Chalid, A. Orhan, S. (2009) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. European Journal of Haematology, 82, 440 449.
100. Wang, J., Hoshino, T., Redner, R.L., Kajigaya, S. Liu, J.M. (1998) ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proceedings of the National Academy of Sciences of the United States of America, 95, 10860 10865.
101. Wang, J., Saunthararajah, Y., Redner, R.L. Liu, J.M. (1999) Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Research, 59, 2766 2769.
102. Weber, D., Badros, A., Jagannath, S., Siegel, D.D., Richon, V., Rizvi, S., Garcia-Vargas, J., Reiser, D. Anderson, K. (2009) Vorinostat and bortezomib in relapsed/refractory multiple myeloma. Clinical Lymphoma & Myeloma, Abstracts Presented at the 13th Annual International Congress on Hematologic Malignancies, 9, S42.
103. Wilson, A.J., Byun, D.-S., Popova, N., Murray, L.B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L.H. Mariadason, J.M. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal of Biological Chemistry, 281, 13548 13558.
104. Wilson, A.J., Byun, D.-S., Nasser, S., Murray, L.B., Ayyanar, K., Arango, D., Figueroa, M., Melnick, A., Kao, G.D., Augenlicht, L.H. Mariadason, J.M. (2008) HDAC4 promotes growth of colon cancer cells via repression of p21. Molecular Biology of the Cell, 19, 4062 4075.
105. Wolf, J.L., Siegel, D., Matous, J., Lonial, S., Goldschmidt, H., Schmitt, S., Vij, R., De Malgalhaes-Silverman, M., Abonour, R., Jalaluddin, M., Li, M., Hazell, K., Bourquelot, P.M., Mateos, M.-V., Anderson, K.C., Spencer, A., Harousseau, J.-L. Blade, J. (2008) A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, 2774.
106. Wu, L.-P., Wang, X., Li, L., Zhao, Y., Lu, S., Yu, Y., Zhou, W., Liu, X., Yang, J., Zheng, Z., Zhang, H., Feng, J., Yang, Y., Wang, H. Zhu, W.-G. (2008) Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Molecular and Cellular Biology, 28, 3219 3235.
107. Xiong, Y., Dowdy, S.C., Podratz, K.C., Jin, F., Attewell, J.R., Eberhardt, N.L. Jiang, S.-W. (2005) Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Research, 65, 2684 2689.
108. Yeung, F., Hoberg, J.E., Ramsey, C.S., Keller, M.D., Jones, D.R., Frye, R.A. Mayo, M.W. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal, 23, 2369 2380.
109. Yoo, C.B. Jones, P.A. (2006) Epigenetic therapy of cancer: past, present and future. Nature Reviews. Drug Discovery, 5, 37 50.
110. You, J.S., Kang, J.K., Lee, E.K., Lee, J.C., Lee, S.H., Jeon, Y.J., Koh, D.H., Ahn, S.H., Seo, D.W., Lee, H.Y., Cho, E.J. Han, J.W. (2007) Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene, 27, 1376 1386.
111. Yuregir, O.O., Yurtcu, E., Kizilkilic, E., Kocer, N.E., Ozdogu, H. Sahin, F.I. (2009) Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. International Journal of Laboratory Hematology, DOI :.
112. Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S.-i. Iwase, H. (2004) HDAC6 expression is correlated with better survival in breast cancer. Clinical Cancer Research, 10, 6962 6968.
113. Zhang, Q.L., Wang, L., Zhang, Y.W., Jiang, X.X., Yang, F., Wu, W.L., Janin, A., Chen, Z., Shen, Z.X., Chen, S.J. Zhao, W.L. (2009) The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia, 23, 1507 1514.
114. Zhu, W.-G., Lakshmanan, R.R., Beal, M.D. Otterson, G.A. (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Research, 61, 1327 1333.
115. Zhu, W.-G., Hileman, T., Ke, Y., Wang, P., Lu, S., Duan, W., Dai, Z., Tong, T., Villalona-Calero, M.A., Plass, C. Otterson, G.A. (2004) 5-Aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. Journal of Biological Chemistry, 279, 15161 15166.